Although low flux NO from constitutive iNOS has been widely reported to support survival, expansion, and therapeutic drug resistance of malignant gliomas, the findings reviewed here are entirely novel with regard to anti-glioma PDT. The gene discussed is NOS2; the disease is glioma.